FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1570259382> ?p ?o ?g. }

• W1570259382 endingPage "698" @default.
• W1570259382 startingPage "692" @default.
• W1570259382 abstract "Chemotherapy for unresectable pancreatic cancer should not only prolong survival but maintain quality of life, considering its limited life expectancy. To achieve these goals, biweekly gemcitabine plus S-1 was assessed in the clinical practice setting.Fifty-two patients with either locally advanced or metastatic pancreatic cancer who received biweekly gemcitabine plus S-1 as a first-line anti-cancer treatment were included in this study. Treatment delivery, toxicity, response, and survival were reviewed to assess the feasibility and efficacy.The completion rate of treatment delivery was 95.1%, with relative dose intensity of 97.1% for gemcitabine and 97.3% for S-1. Overall, grade 3 or worse adverse events were rare, with hematologic toxicities occurring in 5.8%. The objective response rate was 30.8%, and more than a 50% reduction of CA19-9 was observed in 77.1%. Surgical conversion was completed with a margin-negative resection in four patients whose tumor had shrunk for at least 6 months. The median progression-free and overall survivals were 10.4 and 18.2 months, respectively. Reduction of CA19-9 was associated with longer survival.Biweekly gemcitabine plus S-1 may be a good alternative to current standard chemotherapies for unresectable pancreatic cancer with less toxicity and less treatment burden without losing efficacy." @default.
• W1570259382 created "2016-06-24" @default.
• W1570259382 creator A5004867464 @default.
• W1570259382 creator A5013081305 @default.
• W1570259382 creator A5015508395 @default.
• W1570259382 creator A5030164112 @default.
• W1570259382 creator A5044542782 @default.
• W1570259382 creator A5045601646 @default.
• W1570259382 creator A5062379775 @default.
• W1570259382 creator A5062980398 @default.
• W1570259382 creator A5084097657 @default.
• W1570259382 creator A5089883418 @default.
• W1570259382 date "2015-07-01" @default.
• W1570259382 modified "2023-09-25" @default.
• W1570259382 title "Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study" @default.
• W1570259382 cites W1931508686 @default.
• W1570259382 cites W1968626722 @default.
• W1570259382 cites W1973173224 @default.
• W1570259382 cites W2000164816 @default.
• W1570259382 cites W2024826853 @default.
• W1570259382 cites W2031089613 @default.
• W1570259382 cites W2040872961 @default.
• W1570259382 cites W2061174719 @default.
• W1570259382 cites W2067379301 @default.
• W1570259382 cites W2068822158 @default.
• W1570259382 cites W2087362450 @default.
• W1570259382 cites W2095279174 @default.
• W1570259382 cites W2121313610 @default.
• W1570259382 cites W2139248078 @default.
• W1570259382 cites W2143953275 @default.
• W1570259382 cites W2151253787 @default.
• W1570259382 cites W2153244200 @default.
• W1570259382 cites W2155928777 @default.
• W1570259382 cites W2165480504 @default.
• W1570259382 cites W4238493616 @default.
• W1570259382 doi "https://doi.org/10.1002/jhbp.274" @default.
• W1570259382 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26136371" @default.
• W1570259382 hasPublicationYear "2015" @default.
• W1570259382 type Work @default.
• W1570259382 sameAs 1570259382 @default.
• W1570259382 citedByCount "4" @default.
• W1570259382 countsByYear W15702593822017 @default.
• W1570259382 countsByYear W15702593822018 @default.
• W1570259382 countsByYear W15702593822021 @default.
• W1570259382 countsByYear W15702593822022 @default.
• W1570259382 crossrefType "journal-article" @default.
• W1570259382 hasAuthorship W1570259382A5004867464 @default.
• W1570259382 hasAuthorship W1570259382A5013081305 @default.
• W1570259382 hasAuthorship W1570259382A5015508395 @default.
• W1570259382 hasAuthorship W1570259382A5030164112 @default.
• W1570259382 hasAuthorship W1570259382A5044542782 @default.
• W1570259382 hasAuthorship W1570259382A5045601646 @default.
• W1570259382 hasAuthorship W1570259382A5062379775 @default.
• W1570259382 hasAuthorship W1570259382A5062980398 @default.
• W1570259382 hasAuthorship W1570259382A5084097657 @default.
• W1570259382 hasAuthorship W1570259382A5089883418 @default.
• W1570259382 hasBestOaLocation W15702593821 @default.
• W1570259382 hasConcept C121608353 @default.
• W1570259382 hasConcept C126322002 @default.
• W1570259382 hasConcept C141071460 @default.
• W1570259382 hasConcept C143998085 @default.
• W1570259382 hasConcept C197934379 @default.
• W1570259382 hasConcept C2776283816 @default.
• W1570259382 hasConcept C2776694085 @default.
• W1570259382 hasConcept C2780210213 @default.
• W1570259382 hasConcept C2780258809 @default.
• W1570259382 hasConcept C29730261 @default.
• W1570259382 hasConcept C71924100 @default.
• W1570259382 hasConceptScore W1570259382C121608353 @default.
• W1570259382 hasConceptScore W1570259382C126322002 @default.
• W1570259382 hasConceptScore W1570259382C141071460 @default.
• W1570259382 hasConceptScore W1570259382C143998085 @default.
• W1570259382 hasConceptScore W1570259382C197934379 @default.
• W1570259382 hasConceptScore W1570259382C2776283816 @default.
• W1570259382 hasConceptScore W1570259382C2776694085 @default.
• W1570259382 hasConceptScore W1570259382C2780210213 @default.
• W1570259382 hasConceptScore W1570259382C2780258809 @default.
• W1570259382 hasConceptScore W1570259382C29730261 @default.
• W1570259382 hasConceptScore W1570259382C71924100 @default.
• W1570259382 hasIssue "9" @default.
• W1570259382 hasLocation W15702593821 @default.
• W1570259382 hasLocation W15702593822 @default.
• W1570259382 hasOpenAccess W1570259382 @default.
• W1570259382 hasPrimaryLocation W15702593821 @default.
• W1570259382 hasRelatedWork W1969578744 @default.
• W1570259382 hasRelatedWork W2005537476 @default.
• W1570259382 hasRelatedWork W2319496893 @default.
• W1570259382 hasRelatedWork W2349340765 @default.
• W1570259382 hasRelatedWork W2365966720 @default.
• W1570259382 hasRelatedWork W2370585970 @default.
• W1570259382 hasRelatedWork W2376347278 @default.
• W1570259382 hasRelatedWork W3196960728 @default.
• W1570259382 hasRelatedWork W4240456658 @default.
• W1570259382 hasRelatedWork W47495389 @default.
• W1570259382 hasVolume "22" @default.
• W1570259382 isParatext "false" @default.
• W1570259382 isRetracted "false" @default.
• W1570259382 magId "1570259382" @default.

• next